Email

FO ndm.ox.ac.uk ; JO ndm.ox.ac.uk Cc: Trina Racine; EN who.int; Gary (Public Health Agency of Canada) Kobinger; EEN nih.gov (C] Olinger; Peter (NIH/NIAID) [E] Jahrling; © who.int; Larry Zeitlin; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; H© who.int; deborah scott; Shindo, Nikki; © gmail.com; Tara Nyhuis; @ WELLCOME.AC.UK; med.navy.mil; Mike Hensley; Marshall Hoke Subject: RE: Ebola WG Teleconference ISARIC through its Coordinating Centre at U Oxford will be pleased to host a follow-up teleconference this Thursday at 10:00 EDT (15:00 BST). The attachment provides toll-free call-in numbers. For others, the international number is: 0044 203 059 2627. The code is 3119150#. If you plan to participate, please send a confirmation to Kajsa kajsa ,EN@ ndm.ox.ac.uk<mailto:kajsandm.ox.ac.uk> with your contact details, so that we can make list. If you have a specific topic to discuss, please forward that information to me, Kajsa, and Gail Carson. Thanks, fgh From: Marshall Hoke [I cbrint!.com] Sent: 04 August 2014 23:37 To: Mike Hensley Cc: Hayden, Frederick G *HS; Trina Racine; JN who.int; Gary (Public Health Agency of Canada) Kobinger; HE @ 1b .gov [C] Olinger; Peter (NIH/NIAID) [E] Jahrling; who.int; Larry Zeitlin; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; j@who. int; deborah scott; Shindo, Met emia aller Tara Nyhuis Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion Apologies, That last email was meant to read: we hope to be available to discuss further development of the phase 1 protocol in the coming weeks, but would defer to the rest of the group at this time so as to prevent any delays on our end. Thank you for the opportunity to take part in the development of this protocol, and we apologize for any inconvenience this may have caused. Thank you, Marshall Marshall Hoke, B.A. Technical Associate www.cbrintl.com<http://www.cbrintl.com/> This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are further requested to purge this electronic transmission and all copies thereof from your computer system. On Aug 4, 2014, at 8:42 AM, "Mike Hensley" <§@icloud.com<mailto {H@ icloud.com>> wrote: Was late getting the document because of some e-mail issues but finally received. I have no additions or deletions and would consider it a fair and objective assessment of what is available on the therapeutic side of the ledger. Working on references as I'm still at Lisa's home and need to locate a couple on line. Thanks for including me. Mike Hensley On Aug 3, 2014, at 11:38 AM, "Hayden, Frederick G *HS" le hscmail.mcc.virginia.edu<mailto {jjg@hscmail.mcc.virginia.edu>> wrote: Apologies but I left the last reference off by mistake. Please add this very helpful review article: Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 377: ;